Product image of Mifepristona Linepharma (Mifepristone) supplied by GNH India

Mifepristona Linepharma

Active Ingredient:
Mifepristone
Origin:
EU

Mifepristona Linepharma (Mifepristone)

Mifepristone, the active ingredient in Mifepristona Linepharma, is a progesterone receptor antagonist presented as an oral tablet for oral use. It is employed for medical termination of pregnancy and for the management of Cushing's syndrome in appropriately selected patients.

GNH India supplies Mifepristona Linepharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Linepharma

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mifepristone acts on progesterone‑dependent pathways and is indicated for the following clinical situations:

  • Medical termination of pregnancy: induces decidual breakdown and uterine contractility to facilitate pregnancy termination.
  • Cushing's syndrome: antagonizes glucocorticoid receptors to help control hypercortisolism.

How It Works

  • Mifepristone competitively blocks progesterone receptors in the uterus, leading to decidual breakdown, cervical softening, and enhanced uterine contractility. It also antagonizes glucocorticoid receptors, reducing cortisol‑mediated effects, which underlies its use in Cushing's syndrome. The combined receptor antagonism disrupts hormonal support for pregnancy and modulates glucocorticoid activity.

Side Effects

Mifepristone may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Vomiting: occasional episodes after dosing.
  • Abdominal pain or cramping: uterine discomfort.
  • Vaginal bleeding: spotting or heavier flow.
  • Fatigue: general tiredness.
  • Diarrhea: loose stools.

Serious or Rare Side Effects

  • Severe infection: signs of sepsis.
  • Heavy or prolonged bleeding: may require medical attention.
  • Allergic reaction: rash, itching, swelling.
  • Liver toxicity: elevated enzymes or jaundice.
  • Adrenal insufficiency: signs of cortisol deficiency.
  • Rare cardiovascular events: hypertension or thromboembolism.

Precautions & Warnings

Before prescribing Mifepristona Linepharma, clinicians should consider several safety measures.

  • Gestational age verification: confirm eligibility for medical abortion.
  • Medical supervision: ensure administration under qualified health‑care provider.
  • Adrenal function assessment: evaluate for potential insufficiency.
  • Concomitant medication review: check for interactions that may alter efficacy.
  • Contraindication screening: avoid in ectopic pregnancy or severe bleeding disorders.
  • Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Mifepristona Linepharma can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Rifampin: induces hepatic metabolism, reducing effectiveness.
  • Carbamazepine: strong enzyme inducer, may lower drug levels.
  • St. John's wort: herbal inducer, can decrease exposure.
  • Ketoconazole: potent CYP3A4 inhibitor, may increase toxicity.
  • Antifungal azoles (e.g., itraconazole): can raise plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (warfarin): may alter bleeding risk.
  • Antidepressants (SSRIs): monitor for additive side effects.
  • Antihypertensives: watch for blood pressure changes.
  • NSAIDs: increased risk of gastrointestinal irritation.
  • Hormonal contraceptives: possible reduced efficacy.

Frequently Asked Questions

Mifepristona Linepharma contains mifepristone, which is used primarily for the medical termination of early pregnancy and for controlling hypercortisolism in patients with Cushing's syndrome. Both indications rely on the drug’s ability to block progesterone and glucocorticoid receptors.

Mifepristone acts as a competitive antagonist at progesterone receptors, causing decidual breakdown, cervical softening, and uterine contractility that facilitate pregnancy termination. It also blocks glucocorticoid receptors, diminishing cortisol’s effects, which helps manage Cushing's syndrome.

The specific dose and regimen of Mifepristona Linepharma are determined by the prescribing clinician based on the indication, patient characteristics, and local guidelines. Healthcare providers set the appropriate dosage after evaluating each individual case.

Mifepristona Linepharma is contraindicated in ongoing pregnancy except when used for a medically supervised termination. It is not recommended for breastfeeding women because it may pass into milk and affect the infant. Consultation with a healthcare professional is essential before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mifepristona Linepharma (mifepristone) is a progesterone receptor antagonist, whereas other abortifacients such as misoprostol act as prostaglandin analogues that induce uterine contractions. Mifepristone is typically used first to prime the uterus, followed by misoprostol for complete expulsion, offering a two‑step regimen with high efficacy.

Mifepristona Linepharma should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme heat to maintain stability and potency.

The medication is taken orally, usually as a single tablet under the supervision of a qualified healthcare provider. The exact administration protocol, including timing relative to any follow‑up medication, is defined by the prescriber.

Serious risks include heavy or prolonged vaginal bleeding, severe infection, allergic reactions, liver toxicity, and adrenal insufficiency. Patients should be monitored closely for these events, and any signs of severe adverse reactions require immediate medical attention.

Mifepristona Linepharma is contraindicated in individuals with known hypersensitivity to mifepristone, ectopic pregnancy, chronic adrenal insufficiency, severe uncontrolled bleeding disorders, or when used beyond the approved gestational age for medical abortion. A thorough medical assessment is required before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mifepristone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT